Table 2.
Differences in demographic and clinical characteristics, psychological distress, and health-related quality of life between participants and non-participants
| Characteristics | Participants (n = 15) | Non-participants (n = 11) | Difference (p value) |
|---|---|---|---|
| Gender, n (%) male | 13 (87) | 4 (36) | 0.008 |
| Age, mean ± SD (range) (years) | 63 ± 12 (40–80) | 62 ± 8 (52–78) | 0.926 |
| Tumor location, n (%) | 0.986 | ||
| Oral cavity | 4 (27) | 3 (27) | – |
| Oropharynx | 5 (33) | 3 (27) | – |
| Hypopharynx | 0 (0) | 0 (0) | – |
| Larynx | 5 (33) | 4 (36) | – |
| Unknown primary | 1 (7) | 1 (9) | – |
| Disease stage, n (%) | 0.749 | ||
| I | 2 (13) | 2 (18) | – |
| II | 1 (7) | 1 (9) | – |
| III | 5 (33) | 3 (27) | – |
| IV | 7 (46) | 5 (45) | – |
| Type of treatment, n (%) | 0.486 | ||
| CHRT | 8 (53) | 4 (36) | – |
| RT | 4 (27) | 2 (18) | – |
| SURG | 1 (7) | 3 (27) | – |
| TOE + SN | 2 (13) | 2 (18) | – |
| Comorbidity, n (%) | |||
| None | 4 (27) | 3 (27) | 0.683 |
| Mild | 3 (20) | 3 (27) | – |
| Moderate | 7 (47) | 3 (27) | – |
| Severe | 1 (7) | 2 (18) | – |
| Participant (n = 14) | Non-participant (n = 9) | ||
| HADS | |||
| Total score, mean ± SD | 10 ± 8 | 11 ± 5 | 0.587 |
| Depression score ≥8, n (%) | 3 (21 %) | 1 (11 %) | 0.546 |
| Anxiety score ≥8, n (%) | 3 (21 %) | 4 (44 %) | 0.262 |
| Total score >15, n (%) | 3 (21 %) | 2 (22 %) | 0.966 |
| EORTC QLQ-C30, mean ± SD | |||
| Global quality of life | 78 ± 15 | 64 ± 29 | 0.145 |
| Physical function | 87 ± 15 | 81 ± 23 | 0.480 |
| Role function | 88 ± 24 | 74 ± 30 | 0.229 |
| Emotional function | 60 ± 22 | 69 ± 20 | 0.296 |
| Cognitive function | 88 ± 21 | 94 ± 8 | 0.402 |
| Social function | 92 ± 18 | 85 ± 28 | 0.508 |
SD standard deviation, CHRT chemoradiation therapy, EORTC QLQ C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, HADS Hospital Anxiety and Depression Scale, RT radiotherapy, SURG surgery, TOE + SN transoral excision and sentinel node procedure